LT4801B - Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija - Google Patents

Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija Download PDF

Info

Publication number
LT4801B
LT4801B LT1999114A LT99114A LT4801B LT 4801 B LT4801 B LT 4801B LT 1999114 A LT1999114 A LT 1999114A LT 99114 A LT99114 A LT 99114A LT 4801 B LT4801 B LT 4801B
Authority
LT
Lithuania
Prior art keywords
apo
phytosterols
composition
disease
cholesterol
Prior art date
Application number
LT1999114A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99114A (lt
Inventor
Egon Novak
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of LT99114A publication Critical patent/LT99114A/xx
Publication of LT4801B publication Critical patent/LT4801B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT1999114A 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija LT4801B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor

Publications (2)

Publication Number Publication Date
LT99114A LT99114A (lt) 2001-01-25
LT4801B true LT4801B (lt) 2001-06-25

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
LT1999114A LT4801B (lt) 1997-12-18 1999-09-16 Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija

Country Status (18)

Country Link
US (1) US5985936A (xx)
EP (1) EP0967982A2 (xx)
CN (1) CN1252724A (xx)
AU (1) AU1656099A (xx)
BG (1) BG103740A (xx)
BR (1) BR9807577A (xx)
CA (1) CA2281710A1 (xx)
EE (1) EE9900354A (xx)
GE (1) GEP20022783B (xx)
HU (1) HUP0100737A3 (xx)
LT (1) LT4801B (xx)
LV (1) LV12438B (xx)
MD (1) MD1920F2 (xx)
NO (1) NO993979L (xx)
PL (1) PL335421A1 (xx)
RU (1) RU2173151C2 (xx)
SK (1) SK112999A3 (xx)
WO (1) WO1999032097A2 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
US6610320B2 (en) 2000-04-14 2003-08-26 Mars, Incorporated Compositions and methods for improving vascular health
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2005208566A1 (en) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. APOE genetic markers associated with age of onset of Alzheimer's Disease
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2012149111A1 (en) 2011-04-26 2012-11-01 The Regents Of The University Of California Methods of promoting cns neuronal repair by inhibiting lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
WO2021130002A1 (en) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Food supplement for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1994018994A1 (en) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
DK1707572T3 (da) * 1994-09-29 2014-05-12 Univ British Columbia Sterolsammensætninger fra papirmassesæbe
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
ES2285772T3 (es) * 1997-05-15 2007-11-16 University Of Washington Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis.

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOYLES ET AL.: "A role for apoliprotein-E, apoliprotein A-I and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of tjr rat sciatic nerve", J. CLIN. INVEST., 1989, pages 1015 - 1031
ELSHOURBAGY ET AL.: "Apoliprotein E mRNA is abundant in the brain and adreals as well as in liver and is present in other peripheral tissues in rats and marmosets", PROC. NATI. ACAD. SCI. USA, 1985, pages 203 - 207
HANDELMANN ET AL.: "Effects of apolipoprotein E, Beta-very low density lipoproteins and cholesterol on the extension of neurits by rabit dorsal root ganglion neurons in vivo", J. LIPID RES., 1992, pages 1677 - 1688
MULLER M. ET AL.: "A specific 37.000-dalton protein that accumulates in regerating but non-regenerating mammalian", SCIENCE, 1985, pages 499 - 501
STRITTMATTER ET AL.: "Hypothesis: microtubule instability and paired helical filament formation in the Alzheimers desease brain are related to apolipoprotein-E genotype", EXP. NEUROL., 1994, pages 163 - 171
STRITTMATTER ET AL.: "Isoform specific interactions for Alzheimers desease", PROC NATL ACAD SCI U S A., 1994, pages 11183 - 11186

Also Published As

Publication number Publication date
NO993979D0 (no) 1999-08-18
SK112999A3 (en) 2001-11-06
LT99114A (lt) 2001-01-25
MD1920F2 (ro) 2002-05-31
EE9900354A (et) 2000-02-15
MD990262A (en) 2000-06-30
WO1999032097A3 (en) 1999-09-02
HUP0100737A2 (hu) 2001-09-28
BR9807577A (pt) 2001-08-07
US5985936A (en) 1999-11-16
RU2173151C2 (ru) 2001-09-10
LV12438B (en) 2000-09-20
CA2281710A1 (en) 1999-07-01
HUP0100737A3 (en) 2002-07-29
PL335421A1 (en) 2000-04-25
WO1999032097A2 (en) 1999-07-01
LV12438A (en) 2000-03-20
BG103740A (en) 2000-05-31
AU1656099A (en) 1999-07-12
CN1252724A (zh) 2000-05-10
NO993979L (no) 1999-10-13
GEP20022783B (en) 2002-09-25
EP0967982A2 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
LT4801B (lt) Alchaimerio ligos profilaktikai ir sulaikymui skirta kompozicija
Kariv-Inbal et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol
Salem Jr et al. The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Chernick et al. Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier
Martins et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Troutwine et al. Apolipoprotein E and Alzheimer's disease
Vance et al. Cholesterol homeostasis in neurons and glial cells
Yu et al. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits
Karten et al. Mechanisms and consequences of impaired lipid trafficking in Niemann–Pick type C1-deficient mammalian cells
Stein et al. Lipid transfer proteins (LTP) and atherosclerosis
Maria Giudetti et al. The role of brain cholesterol and its oxidized products in Alzheimer's disease
AU9454098A (en) Methods for increasing apoe levels for the treatment of neurodegenerative disease
Montine et al. Central nervous system lipoproteins in Alzheimer's disease.
Teter ApoE-dependent plasticity in Alzheimer’s disease
JP2004505910A (ja) アポリポタンパク質ｅ分泌を誘導するための方法
Turri et al. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Takechi et al. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
Berbée et al. Apolipoprotein CI knock-out mice display impaired memory functions
Dragan et al. Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?
EP2538951A1 (en) Agents and mechanisms for treating hypercholesterolemia
Levi et al. Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation
Blain et al. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease
Xu et al. Lipid metabolism in Alzheimer's and Parkinson's disease
Hone et al. Fat and lipid metabolism and the involvement of apolipoprotein E in Alzheimer's disease
MXPA99007622A (en) Method of preventing and delaying the onset of alzheimer's disease and composition therefor

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20021218